CClinicalTrials.gg
CompletedNCT03237936FASTUpdated Apr 18, 2024Results posted

Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis

A Phase 4 interventional study of 1mg/mL ciclosporin in Keratitis, sponsored by Santen SAS. Completed at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Santen SAS · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered once daily in dry eye disease (DED) patients with severe keratitis, as well as its safety and efficacy.

Read the detailed description

In this phase IV clinical trial the Month 3 visit assessments will be used to assess the efficacy (quality of vision and other parameters) and safety of IKERVIS® in DED patients with severe keratitis.

To assess the effect on the quality of vision of IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily in adult dry eye disease (DED) patients with severe keratitis over 3 months of treatment.

To assess the safety of DED patients with severe keratitis treated with IKERVIS® (1mg/mL ciclosporin) for 3 months.

02

Conditions studied

03

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient eligibility is determined according to the following criteria:

    1. In the opinion of the investigator, the patient is capable of understanding and complying with protocol requirements.
    2. The patient signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures
    3. Male or female patient is aged 18 years or above.
    4. DED patients with persistent severe keratitis at the Screening and

      Baseline Visits defined as the following:

      • CFS score of 3, 4 or 5 on the modified Oxford scale
    5. Patient must be willing and able to undergo and return for scheduled study-related examinations.
    6. The same eye (eligible eye) should fulfill all the above criteria.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of ocular trauma or ocular infection (viral, bacterial, fungal, protozoal) within 90 days before the Screening Visit and any ocular diseases other than dry eye disease requiring topical ocular treatment during the course of the study.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    IKERVIS® (1mg/mL ciclosporin) eye drops

    one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.

    Drug: 1mg/mL ciclosporin

Interventions

  • Drug1mg/mL ciclosporin

    IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment

    Also known as: IKERVIS®

05

What researchers measure

Primary outcomes

  1. Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3.

    Spearman's coefficient of correlation will be calculated at Month 3 between the change from baseline of Corneal Fluorescein Staining (CFS) and respectively the change from baseline of Visual Maintenance Ratio (VRM).

    Time frame: at month 3

06

Results

Posted Apr 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneIKERVIS® (1mg/mL Ciclosporin) Eye Drops
Started17
Completed16
Not completed1

Outcome measures

PrimaryCorrelation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3.

Spearman's coefficient of correlation will be calculated at Month 3 between the change from baseline of Corneal Fluorescein Staining (CFS) and respectively the change from baseline of Visual Maintenance Ratio (VRM).

Time frame:
at month 3
Reported as:
Number · Spearman's coefficient of correlation
Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3.
Spearman's coefficient of correlationIKERVIS® (1mg/mL Ciclosporin) Eye Drops
Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3.-0.7028 (-0.8797 to -0.3158)

Adverse events

Collected over Adverse events were collected from the time of informed consent until the subject's participation in the study ended at Month 3.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IKERVIS® (1mg/mL Ciclosporin) Eye Drops0/17 (0%)0/17 (0%)9/17 (52.9%)
Most frequent other events
Most frequent other events
EventIKERVIS® (1mg/mL Ciclosporin) Eye Drops
EYE IRRITATIONEye disorders3/17
DRY EYEEye disorders2/17
EYE BURNSEye disorders1/17
EYELID OEDEMAEye disorders1/17
PHOTOPHOBIAEye disorders1/17
VISUAL ACUITY REDUCEDEye disorders1/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)IKERVIS® (1mg/mL Ciclosporin) Eye Drops
Mean61.9 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)IKERVIS® (1mg/mL Ciclosporin) Eye Drops
Female13
Male4
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)IKERVIS® (1mg/mL Ciclosporin) Eye Drops
Region of Enrollment
Region of Enrollment(participants)IKERVIS® (1mg/mL Ciclosporin) Eye Drops
France17
07

Study locations

1 site
  • CHU de Brest
    Brest, France
08

References and documents

Study documents

  • Study protocol · Mar 23, 2018
  • Statistical analysis plan · Feb 19, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03237936
Lead sponsor
Santen SAS
Responsible party
Sponsor
First posted
Aug 3, 2017
Start date
Mar 28, 2017
Primary completion
Jul 11, 2018
Completion
Jul 11, 2018
Results posted
Apr 18, 2024
Last update
Apr 18, 2024

Study contacts

Pierre-Jean PISELLA
principal investigator · CHU Bretonneau

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion